newsfilter
← Latest News
GlobeNewswire·

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • Tvardi shares plummeted over 80% on Monday, October 13, 2025, following disappointing preliminary data from the Phase 2 REVERT clinical trial for TTI-101.
  • The study aimed to assess safety, pharmacokinetics, & exploratory outcomes for idiopathic pulmonary fibrosis but failed to meet its goals based on safety data & exploratory efficacy results.
  • Preliminary data showed baseline characteristics were similar across treatment arms except for percent predicted FVC, which was lower in placebo-treated patients compared to TTI-101-treated arms.
  • Investors who suffered significant losses in Tvardi stock or options can contact partner James (Josh) Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss legal rights.
  • Additional information regarding the investigation is available at www.faruqilaw.com/TVRD.